Kiltearn Partners LLP Biogen Inc. Transaction History

Kiltearn Partners LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 14, 2020	SELL	$268.85 - $341.04 $51.1 Million - $64.9 Million	-190,200 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$220.06 - $304.07 $4.62 Million - $6.39 Million	-21,000 Reduced 9.94%	190,200 $56.4 Million
Q3 2019 Nov 14, 2019	SELL	$217.44 - $243.88 $3.76 Million - $4.22 Million	-17,300 Reduced 7.57%	211,200 $48.6 Million
Q2 2019 Jul 30, 2019	SELL	$219.29 - $241.72 $4.8 Million - $5.29 Million	-21,900 Reduced 8.75%	228,500 $53.4 Million
Q1 2019 May 14, 2019	BUY	$216.71 - $338.96 $16.4 Million - $25.6 Million	75,500 Added 43.17%	250,400 $59.2 Million
Q4 2018 Feb 08, 2019	BUY	$278.5 - $352.75 $48.7 Million - $61.7 Million	174,900 New	174,900 $52.6 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Kiltearn Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Kiltearn Partners LLP with notifications on news.